Katja Sockel

Katja Sockel

Auto-generated profile, based on publicly available information

Katja Sockel

Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
JEJan-Niklas Eckardt
Jan-Niklas Eckardt
JMJan Moritz Middeke
Jan Moritz Middeke
SRSebastian Riechert
Sebastian Riechert
TSTim Schmittmann
Tim Schmittmann
ASAnas Shekh Sulaiman
Anas Shekh Sulaiman
MBMartin Bornhäuser
Martin Bornhäuser
The evaluation of bone marrow morphology by experienced hematopathologists is essential in the diagnosis of acute myeloid leukemia (AML); however, it suffers from a lack of standardization and inter-observer variability. Deep learning (DL) can process medical image data and provides data-driven class predictions. Here, we apply a multi-step DL approach to automatically segment cells from bone marrow images, distinguish between AML samples and healthy controls with an area under the receiver operating characteristic (AUROC) of 0.9699, and predict the mutation status of Nucleophosmin 1 (NPM1)—one of the most common mutations in AML—with an AUROC of 0.92 using only image data from bone marrow smears. Utilizing occlusion sensitivity maps, we observed so far unreported morphologic cell features such as a pattern of condensed chromatin and perinuclear lightening zones in myeloblasts of NPM1-mutated AML and prominent nucleoli in wild-type NPM1 AML enabling the DL model to provide accurate class predictions.

22 May 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
Nicolaus KrögerNicolaus Kröger
Nicolaus Kröger
GSGiulia Sbianchi
Giulia Sbianchi
TSTiarlan Sirait
Tiarlan Sirait
CWChristine Wolschke
Christine Wolschke
DBDietrich Beelen
Dietrich Beelen
IYIbrahim Yakoub-Agha
Ibrahim Yakoub-Agha
JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.

4 October 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
CRChristina Rautenberg
Christina Rautenberg
FSFriedrich Stölzel
Friedrich Stölzel
CRChristoph Röllig
Christoph Röllig
MSMatthias Stelljes
Matthias Stelljes
VGVerena Gaidzik
Verena Gaidzik
JMJan Moritz Middeke
Jan Moritz Middeke
To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26–80) treated for therapy-related acute myeloid leukemia (t-AML, 29%) or AML with myelodysplasia-related changes (AML-MRC, 70%). Eighty-six percent received one, 14% two induction cycles, and 10% received consolidation (representing 22% of patients with CR/CRi) with CPX-351. Following induction, CR/CRi rate was 47% including 64% of patients with available information achieving measurable residual disease (MRD) negativity (<10−3) as measured by flow cytometry. After a median follow-up of 9.3 months, median overall survival (OS) was 21 months and 1-year OS rate 64%. In multivariate analysis, complex karyotype predicted lower response (p = 0.0001), while pretreatment with hypomethylating agents (p = 0.02) and adverse European LeukemiaNet 2017 genetic risk (p < 0.0001) were associated with lower OS. Allogeneic hematopoietic cell transplantation (allo-HCT) was performed in 116 patients (62%) resulting in promising outcome (median survival not reached, 1-year OS 73%), especially in MRD-negative patients (p = 0.048). With 69% of patients developing grade III/IV non-hematologic toxicity following induction and a day 30-mortality of 8% the safety profile was consistent with previous findings. These real-world data confirm CPX-351 as efficient treatment for these high-risk AML patients facilitating allo-HCT in many patients with promising outcome after transplantation.

7 July 2023 in Leukemia
Verified
Journal Article
Open access
PDF file
MSMarie Schneider
Marie Schneider
CRClara Rolfs
Clara Rolfs
MTMatthias Trumpp
Matthias Trumpp
SWSusann Winter
Susann Winter
LFLuise Fischer
Luise Fischer
UPUwe Platzbecker
Uwe Platzbecker
Aberrant innate immune signaling has been identified as a potential key driver of the complex pathophysiology of myelodysplastic neoplasms (MDS). This study of a large, clinically and genetically well-characterized cohort of treatment-naïve MDS patients confirms intrinsic activation of inflammatory pathways in general mediated by caspase-1, interleukin (IL)-1β and IL-18 in low-risk (LR)-MDS bone marrow and reveals a previously unrecognized heterogeneity of inflammation between genetically defined LR-MDS subgroups. Principal component analysis resolved two LR-MDS phenotypes with low (cluster 1) and high (cluster 2) levels of IL1B gene expression, respectively. Cluster 1 contained 14/17 SF3B1-mutated cases, while cluster 2 contained 8/8 del(5q) cases. Targeted gene expression analysis of sorted cell populations showed that the majority of the inflammasome-related genes, including IL1B, were primarily expressed in the monocyte compartment, consistent with a dominant role in determining the inflammatory bone marrow environment. However, the highest levels of IL18 expression were found in hematopoietic stem and progenitor cells (HSPCs). The colony forming activity of healthy donor HSPCs exposed to monocytes from LR-MDS was increased by the IL-1β-neutralizing antibody canakinumab. This work reveals distinct inflammatory profiles in LR-MDS that are of likely relevance to the personalization of emerging anti-inflammatory therapies.

14 August 2021 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
UOUta Oelschlaegel
Uta Oelschlaegel
LOLorenz Oelschlaeger
Lorenz Oelschlaeger
MBMalte von Bonin
Malte von Bonin
MKMichael Kramer
Michael Kramer
KSKatja Sockel
Katja Sockel
UPUwe Platzbecker
Uwe Platzbecker
Background: Flow cytometry (FCM) is a co‐criterion in myelodysplastic syndromes (MDS) diagnostics according to the WHO classification. The presented study compared diagnostic power and prognostic impact of different FCM‐based scores.Methods: A total of 807 bone marrow (BM) samples of patients with cytopenia (543 MDS, 153 non‐clonal cytopenias, 111 non‐MDS myeloid malignancies) and 78 healthy controls have been investigated using a standardized 8‐color‐FCM procedure. FCSS, Ogata‐score, iFS, RED‐score, and ELN‐NEC were analyzed for sensitivity and specificity in comparison to standard diagnostic tools. Median follow up for patients was 26 month (range: 0.2–89).Results: The iFS showed the highest accuracy (80%) with the best balance between sensitivity (79%) and specificity (86%). This was also valid in MDS with very low IPSS‐R and even in MDS without ring sideroblasts, with normal blast count and karyotype, where iFS could confirm diagnosis in 62% and 65% of patients. Besides the high diagnostic power, the established iFS category “consistent with MDS” was associated with inferior overall survival (OS) independent from WHO classification (median: 51 month vs. not reached,p < 0.0001). Remarkably, this iFS category redefined a subgroup of patients with worse OS within IPSS‐R low‐risk category (73 month vs. not reached,p = 0.0433). Finally, multivariable analysis showed that iFS added independent prognostic information regarding OS besides IPSS‐R.Conclusions: The iFS separates non‐clonal cytopenias and MDS with the highest accuracy, provided information in addition to standard diagnostic procedures, and refined established prognostic tools for outcome prediction.

5 September 2022 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
DKDesiree Kunadt
Desiree Kunadt
SSSebastian Stasik
Sebastian Stasik
KMKlaus Metzeler H Metzeler
Klaus Metzeler H Metzeler
CRChristoph Röllig
Christoph Röllig
CSChristoph Schliemann
Christoph Schliemann
FSFriedrich Stölzel
Friedrich Stölzel
Background: The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutatedIDH1/2has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first complete remission (CR1) undergoing alloHCT or conventional chemo-consolidation and investigated outcome in respect toIDH1/2mutational subgroups (IDH1R132C, R132H and IDH2 R140Q, R172K).Methods: Genomic DNA was extracted from bone marrow or peripheral blood samples at diagnosis and analyzed forIDHmutations with denaturing high-performance liquid chromatography, Sanger sequencing and targeted myeloid panel next-generation sequencing, respectively. Statistical as-treated analyses were performed using R and standard statistical methods (Kruskal–Wallis test for continuous variables, Chi-square test for categorical variables, Cox regression for univariate and multivariable models), incorporating alloHCT as a time-dependent covariate.Results: Among 3234 patients achieving CR1, 7.8% harboredIDH1mutations (36% R132C and 47% R132H) and 10.9% carriedIDH2mutations (77% R140Q and 19% R172K). 852 patients underwent alloHCT in CR1. Within the alloHCT group, 6.2% had anIDH1mutation (43.4% R132C and 41.4% R132H) and 10% were characterized by anIDH2mutation (71.8% R140Q and 24.7% R172K). Variants IDH1 R132C and IDH2 R172K showed a significant benefit from alloHCT for OS (p = .017 andp = .049) and RFS (HR = 0.42,p = .048 andp = .009) compared with chemotherapy only. AlloHCT in IDH2 R140Q mutated AML resulted in longer RFS (HR = 0.4,p = .002).Conclusion: In this large as-treated analysis, we showed that alloHCT is able to overcome the negative prognostic impact of certainIDHmutational subclasses in first-line consolidation treatment and could pending prognostic validation, provide prognostic value for AML risk stratification and therapeutic decision making.